{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:59:20Z","timestamp":1791460760281,"version":"4.3.4"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:00:00Z","timestamp":1613692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Brazil is the largest country in South America and the most genetically heterogeneous. The aim of the present study was to determine the prevalence of germline pathogenic variants (PVs) in Brazilian patients with breast cancer (BC) who underwent genetic counseling and genetic testing at a tertiary Oncology Center. We performed a retrospective analysis of the medical records of Brazilian patients with BC referred to genetic counseling and genetic testing between August 2017 and August 2019. A total of 224 unrelated patients were included in this study. Premenopausal women represented 68.7% of the cohort. The median age at BC diagnosis was 45 years. Multigene panel testing was performed in 219 patients, five patients performed single gene analysis or family variant testing. Forty-eight germline PVs distributed among 13 genes were detected in 20.5% of the patients (46\/224). Eighty-five percent of the patients (91\/224) fulfilled NCCN hereditary BC testing criteria. Among these patients, 23.5% harbored PVs (45\/191). In the group of patients that did not meet NCCN criteria, PV detection rate was 3% (1\/33). A total of 61% of the patients (28\/46) harbored a PV in a high-penetrance BC gene: 19 (8.5%) <jats:italic>BRCA1\/2<\/jats:italic>, 8 (3.5%) <jats:italic>TP53<\/jats:italic>, 1 (0.5%) <jats:italic>PALB2<\/jats:italic>. Moderate penetrance genes (<jats:italic>ATM<\/jats:italic>, <jats:italic>CHEK2<\/jats:italic>) represented 15.2% (7\/46) of the positive results. PVs detection was statistically associated (p&lt;0.05) with BC diagnosis before age 45, high-grade tumors, bilateral BC, history of multiple primary cancers, and family history of pancreatic cancer. According to the current hereditary cancer guidelines, 17.4% (39\/224) of the patients had actionable variants. Nine percent of the patients (20\/224) had actionable variants in non-<jats:italic>BRCA<\/jats:italic> genes, it represented 43.5% of the positive results and 51.2% of the actionable variants. Considering the observed prevalence of PVs in actionable genes beyond <jats:italic>BRCA1\/2<\/jats:italic> (9%, 20\/224), multigene panel testing may offer an effective first-tier diagnostic approach in this population.<\/jats:p>","DOI":"10.1371\/journal.pone.0247363","type":"journal-article","created":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T04:14:49Z","timestamp":1613794489000},"page":"e0247363","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":29,"title":["Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8446-3675","authenticated-orcid":true,"given":"Renata Lazari","family":"Sandoval","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7192-3425","authenticated-orcid":true,"given":"Ana Carolina Rathsam","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Meirelles","family":"Barbalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele Xavier","family":"Assad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romualdo","family":"Barroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Polidorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Henrique","family":"dos Anjos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9a Discaciati","family":"de Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Carolina Salles de Mendon\u00e7a","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo dos Santos","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Isabel","family":"Achatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,2,19]]},"reference":[{"issue":"2","key":"pone.0247363.ref001","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/PAP.0000000000000177","article-title":"Hereditary Breast and Ovarian Cancer Syndrome: Moving Beyond BRCA1 and BRCA2","volume":"25","author":"LN Hoang","year":"2018","journal-title":"Adv Anat Pathol"},{"issue":"5","key":"pone.0247363.ref002","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-017-0468-y","article-title":"The Changing Landscape of Genetic Testing for Inherited Breast Cancer Predisposition","volume":"18","author":"A Afghahi","year":"2017","journal-title":"Curr Treat Options Oncol"},{"issue":"18","key":"pone.0247363.ref003","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1200\/JCO.20.00299","article-title":"Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline","volume":"38","author":"NM Tung","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"pone.0247363.ref004","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12282-017-0803-y","article-title":"Cost-effectiveness of surveillance and prevention strategies in BRCA1\/2 mutation carriers","volume":"25","author":"H Yamauchi","year":"2018","journal-title":"Breast Cancer"},{"issue":"7","key":"pone.0247363.ref005","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jamaoncol.2015.2690","article-title":"Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment","volume":"1","author":"A Desmond","year":"2015","journal-title":"JAMA Oncol"},{"key":"pone.0247363.ref006","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/978-3-319-70197-4_8","article-title":"Multi-gene panel testing in breast cancer management","volume":"173","author":"C Fountzilas","year":"2018","journal-title":"Cancer Treat Res"},{"issue":"4","key":"pone.0247363.ref007","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41436-018-0277-0","article-title":"Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility","volume":"21","author":"SM Rowley","year":"2019","journal-title":"Genet Med"},{"issue":"1","key":"pone.0247363.ref008","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrclinonc.2015.173","article-title":"Population genetic testing for cancer susceptibility: Founder mutations to genomes","volume":"13","author":"WD Foulkes","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"pone.0247363.ref009","article-title":"Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1 \/ 2 -Related Cancer in Women: A Systematic Review for the U. S","author":"HD Nelson","year":"2019","journal-title":"Preventive Services Task Force"},{"issue":"11","key":"pone.0247363.ref010","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.ejca.2007.04.023","article-title":"Genetic epidemiology of BRCA mutations\u2014family history detects less than 50% of the mutation carriers","volume":"43","author":"P M\u00f8ller","year":"2007","journal-title":"Eur J Cancer"},{"issue":"36","key":"pone.0247363.ref011","doi-asserted-by":"crossref","first-page":"60487","DOI":"10.18632\/oncotarget.10814","article-title":"Spectrum of BRCA1\/2 variants in 940 patients from Argentina including novel, deleterious and recurrent germline mutations: Impact on healthcare and clinical practice","volume":"8","author":"AR Solano","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"pone.0247363.ref012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-27315-2","article-title":"The germline mutational landscape of BRCA1 and BRCA2 in Brazil","volume":"8","author":"EI Palmero","year":"2018","journal-title":"Sci Rep"},{"issue":"3","key":"pone.0247363.ref013","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s10549-018-4938-0","article-title":"A portrait of germline mutation in Brazilian at-risk for hereditary breast cancer","volume":"172","author":"AR de Souza Timoteo","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"pone.0247363.ref014","doi-asserted-by":"crossref","DOI":"10.1186\/s12920-019-0652-y","article-title":"Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: Analysis of a 21 gene panel in the Brazilian population","volume":"13","author":"S Da Costa E Silva Carvalho","year":"2020","journal-title":"BMC Med Genomics"},{"issue":"3","key":"pone.0247363.ref015","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1590\/1678-4685-gmb-2018-0076","article-title":"A systematic scoping review of the genetic ancestry of the brazilian population","volume":"42","author":"AM de Souza","year":"2019","journal-title":"Genet Mol Biol"},{"issue":"3","key":"pone.0247363.ref016","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s12282-018-00938-z","article-title":"Mutation screening of TP53, CHEK2 and BRCA genes in patients at high risk for hereditary breast and ovarian cancer (HBOC) in Brazil","volume":"26","author":"NM Cipriano","year":"2019","journal-title":"Breast Cancer"},{"issue":"5","key":"pone.0247363.ref017","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"S Richards","year":"2015","journal-title":"Genet Med"},{"key":"pone.0247363.ref018","unstructured":"National Comprehensive Cancer Network. Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic (Version 1.2021) [Internet]. 2021 [cited 2020 Sep 9]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast-screening.pdf"},{"issue":"9","key":"pone.0247363.ref019","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamaoncol.2017.0424","article-title":"Associations between cancer predisposition testing panel genes and breast cancer","volume":"3","author":"FJ Couch","year":"2017","journal-title":"JAMA Oncol"},{"issue":"8","key":"pone.0247363.ref020","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/jnci\/djy106","article-title":"Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing","volume":"110","author":"H Shimelis","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"pone.0247363.ref021","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/gim.2017.254","article-title":"MSH6 and PMS2 germ-line pathogenic variants implicated in Lynch syndrome are associated with breast cancer","volume":"20","author":"ME Roberts","year":"2018","journal-title":"Genet Med"},{"issue":"1","key":"pone.0247363.ref022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-019-1137-9","article-title":"Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer","volume":"21","author":"N Weber-Lassalle","year":"2019","journal-title":"Breast Cancer Res"},{"issue":"11","key":"pone.0247363.ref023","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/gim.2014.40","article-title":"Utilization of multigene panels in hereditary cancer predisposition testing: Analysis of more than 2,000 patients","volume":"16","author":"H Laduca","year":"2014","journal-title":"Genet Med"},{"key":"pone.0247363.ref024","author":"KA Wetterstrand","journal-title":"DNA sequencing costs: data from the NHGRI genome sequencing program"},{"issue":"8","key":"pone.0247363.ref025","article-title":"Universal Genetic Testing for All Breast Cancer Patients","volume":"33","author":"MS Copur","year":"2019","journal-title":"Oncology"},{"issue":"11","key":"pone.0247363.ref026","doi-asserted-by":"crossref","first-page":"e765","DOI":"10.1016\/j.amjmed.2019.03.012","article-title":"Universal Multigene Panel Testing in all Breast Cancer Patients","volume":"132","author":"S Sorscher","year":"2019","journal-title":"Am J Med"},{"key":"pone.0247363.ref027","first-page":"1","article-title":"Germline genetic testing in breast cancer: Rationale for the testing of all women diagnosed by the age of 60 years and for risk-based testing of those older than 60 years","author":"V Desai N","year":"2020","journal-title":"Cancer"},{"issue":"3","key":"pone.0247363.ref028","first-page":"379","volume":"26","author":"M Cruz-correa","year":"2018","journal-title":"Clinical Cancer Genetics Disparities among Latinos"},{"key":"pone.0247363.ref029","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1200\/JGO.19.00170","article-title":"Recommendations for advancing the diagnosis and management of hereditary breast and ovarian cancer in Brazil","volume":"6","author":"MI Achatz","year":"2020","journal-title":"J Glob Oncol"},{"key":"pone.0247363.ref030","unstructured":"Dados gerais [Internet]. The National Agency of Supplementary Health. [cited 2020 Oct 1]. Available from: http:\/\/www.ans.gov.br\/index.php\/aans\/quem-somos\/227-dados-gerais"},{"issue":"2","key":"pone.0247363.ref031","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/cas.14242","article-title":"Prevalence of hereditary breast and ovarian cancer (HBOC) predisposition gene mutations among 882 HBOC high-risk Chinese individuals","volume":"111","author":"D Shao","year":"2020","journal-title":"Cancer Sci"},{"issue":"3","key":"pone.0247363.ref032","doi-asserted-by":"crossref","first-page":"697","DOI":"10.4143\/crt.2019.559","article-title":"Detection of Germline Mutations in Breast Cancer Patients with Clinical Features of Hereditary Cancer Syndrome Using a Multi-Gene Panel Test","volume":"52","author":"HC Shin","year":"2020","journal-title":"Cancer Res Treat"},{"issue":"1","key":"pone.0247363.ref033","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10689-017-0004-z","article-title":"A multi-gene panel study in hereditary breast and ovarian cancer in Colombia","volume":"17","author":"AM Cock-Rada","year":"2018","journal-title":"Fam Cancer"},{"issue":"12","key":"pone.0247363.ref034","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1007\/s00432-018-2763-9","article-title":"Multigene panel testing beyond BRCA1\/2 in breast\/ovarian cancer Spanish families and clinical actionability of findings","volume":"144","author":"S Bonache","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9","key":"pone.0247363.ref035","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrclinonc.2016.90","article-title":"Counselling framework for moderate-penetrance cancer-susceptibility mutations","volume":"13","author":"N Tung","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"pone.0247363.ref036","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1590\/S1415-47572009005000058","article-title":"Population prevalence of hereditary breast cancer phenotypes and implementation of a genetic cancer risk assessment program in southern Brazil","volume":"32","author":"EI Palmero","year":"2009","journal-title":"Genet Mol Biol"},{"issue":"May","key":"pone.0247363.ref037","first-page":"1","article-title":"Germline mutations in BRCA1, BRCA2, CHEK2 and TP53 in patients at high-risk for HBOC: Characterizing a Northeast Brazilian Population","volume":"1","author":"GES Felix","year":"2014","journal-title":"Hum Genome Var"},{"issue":"1","key":"pone.0247363.ref038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2350-15-55","article-title":"Hereditary breast and ovarian cancer: Assessment of point mutations and copy number variations in Brazilian patients","volume":"15","author":"FC Silva","year":"2014","journal-title":"BMC Med Genet"},{"issue":"4","key":"pone.0247363.ref039","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1590\/S0004-28032012000400008","article-title":"CHEK2 1100delC germline mutation: A frequency study in hereditary breast and colon cancer Brazilian families","volume":"49","author":"J Abud","year":"2012","journal-title":"Arq Gastroenterol"},{"issue":"6","key":"pone.0247363.ref040","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jmoldx.2017.07.004","article-title":"Clinical Validation of Copy Number Variant Detection from Targeted Next-Generation Sequencing Panels","volume":"19","author":"J Kerkhof","year":"2017","journal-title":"J Mol Diagnostics"},{"issue":"2","key":"pone.0247363.ref041","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1590\/1678-4685-gmb-2014-0350","article-title":"BRCA1 and BRCA2 rearrangements in Brazilian individuals with hereditary breast and ovarian cancer syndrome","volume":"39","author":"IP Ewald","year":"2016","journal-title":"Genet Mol Biol"},{"issue":"6","key":"pone.0247363.ref042","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1371\/journal.pone.0099893","article-title":"Prevalence of the TP53 p.R337H mutation in breast cancer patients in Brazil","volume":"9","author":"J Giacomazzi","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"pone.0247363.ref043","first-page":"1","article-title":"TP53 p.Arg337His germline mutation prevalence in Southern Brazil: Further evidence for mutation testing in young breast cancer patients","volume":"13","author":"EC Hahn","year":"2018","journal-title":"PLoS One"},{"issue":"1\u20132","key":"pone.0247363.ref044","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.canlet.2005.12.039","article-title":"The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families","volume":"245","author":"MIW Achatz","year":"2007","journal-title":"Cancer Lett"},{"issue":"1","key":"pone.0247363.ref045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/dju380","article-title":"Cost-effectiveness of population screening for BRCA mutations in Ashkenazi Jewish women compared with family history-based testing","volume":"107","author":"R Manchanda","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"pone.0247363.ref046","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"KB Kuchenbaecker","year":"2017","journal-title":"JAMA\u2014J Am Med Assoc"},{"issue":"9","key":"pone.0247363.ref047","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12092415","article-title":"Detection of germline mutations in a cohort of 139 patients with bilateral breast cancer by multi-gene panel testing: Impact of pathogenic variants in other genes beyond brca1\/2","volume":"12","author":"D Fanale","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"pone.0247363.ref048","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10549-017-4181-0","article-title":"Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients","volume":"163","author":"B Crawford","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"pone.0247363.ref049","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/ijc.30197","article-title":"Risk of extracolonic cancers for people with biallelic and monoallelic mutations in MUTYH","volume":"139","author":"AK Win","year":"2016","journal-title":"Int J Cancer"},{"issue":"2","key":"pone.0247363.ref050","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10689-018-00114-4","article-title":"Monoallelic MUTYH carrier status is not associated with increased breast cancer risk in a multigene panel cohort","volume":"18","author":"K Fulk","year":"2019","journal-title":"Fam Cancer"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0247363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T04:15:42Z","timestamp":1613794542000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0247363"}},"subtitle":[],"editor":[{"given":"Amanda Ewart","family":"Toland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,2,19]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0247363","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,19]]}}}